News Headlines Article

Genentech wins FDA approval of first new bladder cancer drug in 30 years
San Francisco Business Times

Just two months after scoring the promise of a quick regulatory review, Genentech Inc. won Food and Drug Administration approval Wednesday of a new type of cancer immunotherapy drug against advanced bladder cancer that has spread to other parts of the body. The FDA’s approval of the monoclonal antibody atezolizumab, which will be sold as Tecentriq, is significant for a couple of reasons, mainly for patients with metastatic bladder cancer. No new treatment for the cancer, which is expected to be diagnosed in 76,000 Americans this year, has been approved for 30 years, and patients today are subjected to grueling, toxic platinum-based chemotherapies.